-+ 0.00%
-+ 0.00%
-+ 0.00%

BENITEC BIOPHARMA REPORTS POSITIVE INTERIM CLINICAL RESULTS FOR THREE SUBJECTS TREATED WITH BB-301 IN PHASE 1B/2A STUDY TO BE PRESENTED AT THE 2025 MUSCULAR DYSTROPHY ASSOCIATION CLINICAL & SCIENTIFIC CONFERENCE

Reuters·03/19/2025 11:00:02

Please log in to view news